Antibacterial prophylaxis of febrile neutropenia is not effective in the pre-engraftment period in pediatric allogeneic hematopoietic stem cell transplantation.
Transpl Infect Dis. 2020 May 23;:e13340
Authors: Ricci E, Mesini A, Bandettini R, Faraci M, Castagnola E
the recently published guideline by Lehrnbecher et al  on antibacterial prophylaxis for prevention of febrile neutropenia in cancer children gives a weak recommendation with a moderate quality evidence not to administer systemic antibacterial prophylaxis for children undergoing allogeneic hematopoietic stem cell transplantation (HSCT). This recommendation was based mainly on a single randomized clinical trial , showing no effectiveness of levofloxacin compared to no prophylaxis (effectiveness 11.0% vs 17.3%; risk difference: 6.3%; p =0.06).
PMID: 32445434 [PubMed - as supplied by publisher]